Advertisement

Molecular Neurobiology

, Volume 53, Issue 6, pp 4046–4053 | Cite as

Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials

  • Sheng Chen
  • LiGen Shi
  • Feng Liang
  • Liang Xu
  • Doycheva Desislava
  • Qun Wu
  • Jianmin Zhang
Article

Abstract

Recently, two high-quality clinical randomized controlled trials (RCTs) regarding the preventive effect of exogenous melatonin on delirium drew inconsistent conclusions. We therefore performed a systemic review to explore whether melatonin had a benefit on delirium prevention. MEDLINE, EMBASE, and Cochrane Library were searched from January 1980 to April 2015 for English language studies. After strict selection and evaluation, the data were extracted from the included four RCTs. The primary outcome of this meta-analysis was the incidence of delirium. The secondary outcome was the improvement of sleep–wake rhythm. A total of four RCTs with 669 elderly patients were included in the present study. Melatonin group showed a tendency to decrease the incidence of delirium (relative risk [RR] 0.41, 95 % confidence interval [CI] 0.15 to 1.13; P = 0.08) compared with control group. In subgroup analysis of the elderly patients in medical wards, melatonin supplementation decreased the incidence of delirium by 75 % (RR 0.25, 95 % CI 0.07 to 0.88; P = 0.03), but not in sleep–wake disturbance (RR 1.24, 95 % CI 0.51 to 3.00; P = 0.64). No differences were found in the incidence of delirium between the two groups in the elderly patients that were presented to surgical wards. In conclusion, melatonin supplementation had a significant preventive effect in decreasing the incidence of delirium in elderly patients that were presented to medical wards. Further studies should provide sufficient evidence about the effect of melatonin on delirium in a large sample size.

Keywords

Delirium Melatonin Sleep–wake cycle Meta-analysis 

Notes

Acknowledgments

This study was supported by National Natural Science Foundation of China (No. 81171096 and No. 81371433) to JM Zhang and National Natural Science Foundation of China (No. 81271273) to Q Wu.

Conflict of interest

The authors report no financial or other relationship relevant to the subject of this article.

References:

  1. 1.
    Gray SL, Lai KV, Larson EB (1999) Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf 21(2):101–122. doi: 10.2165/00002018-199921020-00004 CrossRefPubMedGoogle Scholar
  2. 2.
    de Jonghe A, Korevaar JC, van Munster BC, de Rooij SE (2010) Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatr 25(12):1201–1208. doi: 10.1002/gps.2454 CrossRefGoogle Scholar
  3. 3.
    Kiely DK, Marcantonio ER, Inouye SK, Shaffer ML, Bergmann MA, Yang FM, Fearing MA, Jones RN (2009) Persistent delirium predicts greater mortality. J Am Geriatr Soc 57(1):55–61. doi: 10.1111/j.1532-5415.2008.02092.x CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK (2008) One-year health care costs associated with delirium in the elderly population. Arch Intern Med 168(1):27–32. doi: 10.1001/archinternmed.2007.4 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Friedman JI, Soleimani L, McGonigle DP, Egol C, Silverstein JH (2014) Pharmacological treatments of non-substance-withdrawal delirium: a systematic review of prospective trials. Am J Psychiatry 171(2):151–159. doi: 10.1176/appi.ajp.2013.13040458 CrossRefPubMedGoogle Scholar
  6. 6.
    de Rooij SE, van Munster BC, de Jonghe A (2014) Melatonin prophylaxis in delirium: panacea or paradigm shift? JAMA Psychiatry 71(4):364–365. doi: 10.1001/jamapsychiatry.2013.4532 CrossRefPubMedGoogle Scholar
  7. 7.
    Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP (2007) Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 21(12):995–1018. doi: 10.2165/00023210-200721120-00004 CrossRefPubMedGoogle Scholar
  8. 8.
    Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM, Reiter RJ (2003) Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 34(1):75–78. doi: 10.1034/j.1600-079X.2003.02111.x CrossRefPubMedGoogle Scholar
  9. 9.
    Fukada Y, Okano T (2002) Circadian clock system in the pineal gland. Mol Neurobiol 25(1):19–30. doi: 10.1385/mn:25:1:019 CrossRefPubMedGoogle Scholar
  10. 10.
    Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, Shenkman L (2000) Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study. Chronobiol Int 17(1):71–76. doi: 10.1081/CBI-100101033 CrossRefPubMedGoogle Scholar
  11. 11.
    Cronin AJ, Keifer JC, Davies MF, King TS, Bixler EO (2000) Melatonin secretion after surgery. Lancet 356(9237):1244–1245. doi: 10.1016/S0140-6736(00)02795-1 CrossRefPubMedGoogle Scholar
  12. 12.
    Miyazaki T, Kuwano H, Kato H, Ando H, Kimura H, Inose T, Ohno T, Suzuki M et al (2003) Correlation between serum melatonin circadian rhythm and intensive care unit psychosis after thoracic esophagectomy. Surgery 133(6):662–668. doi: 10.1067/msy.2003.149 CrossRefPubMedGoogle Scholar
  13. 13.
    Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, Ruscica M, Dozio E et al (2010) Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res 48(2):142–147. doi: 10.1111/j.1600-079X.2009.00737.x CrossRefPubMedGoogle Scholar
  14. 14.
    Yoshitaka S, Egi M, Morimatsu H, Kanazawa T, Toda Y, Morita K (2013) Perioperative plasma melatonin concentration in postoperative critically ill patients: its association with delirium. J Crit Care 28(3):236–242. doi: 10.1016/j.jcrc.2012.11.004 CrossRefPubMedGoogle Scholar
  15. 15.
    Magri F, Sarra S, Cinchetti W, Guazzoni V, Fioravanti M, Cravello L, Ferrari E (2004) Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. J Pineal Res 36(4):256–261. doi: 10.1111/j.1600-079X.2004.00125.x CrossRefPubMedGoogle Scholar
  16. 16.
    Kennaway DJ, Lushington K, Dawson D, Lack L, van den Heuvel C, Rogers N (1999) Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature. J Pineal Res 27(4):210–220. doi: 10.1111/j.1600-079X.1999.tb00617.x CrossRefPubMedGoogle Scholar
  17. 17.
    Balan S, Leibovitz A, Zila SO, Ruth M, Chana W, Yassica B, Rahel B, Richard G et al (2003) The relation between the clinical subtypes of delirium and the urinary level of 6-SMT. J Neuropsychiatr Clin Neurosci 15(3):363–366. doi: 10.1176/appi.neuropsych.15.3.363 CrossRefGoogle Scholar
  18. 18.
    Mahlberg R, Tilmann A, Salewski L, Kunz D (2006) Normative data on the daily profile of urinary 6-sulfatoxymelatonin in healthy subjects between the ages of 20 and 84. Psychoneuroendocrinology 31(5):634–641. doi: 10.1016/j.psyneuen.2006.01.009 CrossRefPubMedGoogle Scholar
  19. 19.
    Fitzgerald JM, Adamis D, Trzepacz PT, O'Regan N, Timmons S, Dunne C, Meagher DJ (2013) Delirium: a disturbance of circadian integrity? Med Hypotheses 81(4):568–576. doi: 10.1016/j.mehy.2013.06.032 CrossRefPubMedGoogle Scholar
  20. 20.
    Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S et al (2005) Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48(2):301–310. doi: 10.1016/j.neuropharm.2004.09.007 CrossRefPubMedGoogle Scholar
  21. 21.
    Wurtman R (2006) Ramelteon: a novel treatment for the treatment of insomnia. Expert Rev Neurother 6(7):957–964. doi: 10.1586/14737175.6.7.957 CrossRefPubMedGoogle Scholar
  22. 22.
    Hanania M, Kitain E (2002) Melatonin for treatment and prevention of postoperative delirium. Anesth Analg 94((2):338–339, table of contentsPubMedGoogle Scholar
  23. 23.
    Lammers M, Ahmed AI (2013) Melatonin for sundown syndrome and delirium in dementia: is it effective? J Am Geriatr Soc 61(6):1045–1046. doi: 10.1111/jgs.12296 CrossRefPubMedGoogle Scholar
  24. 24.
    Kimura R, Mori K, Kumazaki H, Yanagida M, Taguchi S, Matsunaga H (2011) Treatment of delirium with ramelteon: initial experience in three patients. Gen Hosp Psychiatry 33(4):407–409. doi: 10.1016/j.genhosppsych.2011.03.013 CrossRefPubMedGoogle Scholar
  25. 25.
    Furuya M, Miyaoka T, Yasuda H, Yamashita S, Tanaka I, Otsuka S, Wake R, Horiguchi J (2012) Marked improvement in delirium with ramelteon: five case reports. Psychogeriatr: Off J Jpn Psychogeriatr Soc 12(4):259–262. doi: 10.1111/j.1479-8301.2012.00422.x CrossRefGoogle Scholar
  26. 26.
    Ohta T, Murao K, Miyake K, Takemoto K (2013) Melatonin receptor agonists for treating delirium in elderly patients with acute stroke. J Stroke Cerebrovas Dis: Off J Natl Stroke Assoc 22(7):1107–1110. doi: 10.1016/j.jstrokecerebrovasdis.2012.08.012 CrossRefGoogle Scholar
  27. 27.
    Tsuda A, Nishimura K, Naganawa E, Otsubo T, Ishigooka J (2013) Successfully treated delirium in an extremely elderly patient by switching from risperidone to ramelteon. Psychiatry Clin Neurosci 67(2):130. doi: 10.1111/pcn.12016 CrossRefPubMedGoogle Scholar
  28. 28.
    Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, Nakamura H (2014) Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry 71(4):397–403. doi: 10.1001/jamapsychiatry.2013.3320 CrossRefPubMedGoogle Scholar
  29. 29.
    de Jonghe A, van Munster BC, Goslings JC, Kloen P, van Rees C, Wolvius R, van Velde R, Levi M et al (2014) Effect of melatonin on incidence of delirium among patients with hip fracture: a multicentre, double-blind randomized controlled trial. CMAJ: Can Med Assoc J 186(14):E547–E556. doi: 10.1503/cmaj.140495 CrossRefGoogle Scholar
  30. 30.
    Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M (2011) Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 26(7):687–694. doi: 10.1002/gps.2582 CrossRefPubMedGoogle Scholar
  31. 31.
    Sultan SS (2010) Assessment of role of perioperative melatonin in prevention and treatment of postoperative delirium after hip arthroplasty under spinal anesthesia in the elderly. Saudi J Anaesth 4(3):169–173. doi: 10.4103/1658-354x.71132 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. doi: 10.1136/bmj.b2700 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Shi L, Pu J, Xu L, Malaguit J, Zhang J, Chen S (2014) The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population- an updated meta-analysis. BMC Neurol 14(1):251. doi: 10.1186/s12883-014-0251-7 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Parikh SS, Chung F (1995) Postoperative delirium in the elderly. Anesth Analg 80(6):1223–1232PubMedGoogle Scholar
  35. 35.
    de Rooij SE, van Munster BC (2013) Melatonin deficiency hypothesis in delirium: a synthesis of current evidence. Rejuvenation Res 16(4):273–278. doi: 10.1089/rej.2012.1405 CrossRefPubMedGoogle Scholar
  36. 36.
    Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I (2005) Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9(1):41–50. doi: 10.1016/j.smrv.2004.06.004 CrossRefPubMedGoogle Scholar
  37. 37.
    Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP et al (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332(7538):385–393. doi: 10.1136/bmj.38731.532766.F6 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Liu J, Wang LN (2012) Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. Int J Clin Pract 66(9):867–873. doi: 10.1111/j.1742-1241.2012.02987.x CrossRefPubMedGoogle Scholar
  39. 39.
    Kuriyama A, Honda M, Hayashino Y (2014) Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med 15(4):385–392. doi: 10.1016/j.sleep.2013.11.788 CrossRefPubMedGoogle Scholar
  40. 40.
    Maldonado JR (2008) Pathoetiological model of delirium: a comprehensive understanding of the neurobiology of delirium and an evidence-based approach to prevention and treatment. Crit Care Clin 24(4):789–856. doi: 10.1016/j.ccc.2008.06.004, ixCrossRefPubMedGoogle Scholar
  41. 41.
    Zisapel N, Laudon M (1982) Dopamine release induced by electrical field stimulation of rat hypothalamus in vitro: inhibition by melatonin. Biochem Biophys Res Commun 104(4):1610–1616CrossRefPubMedGoogle Scholar
  42. 42.
    Maclullich AM, Ferguson KJ, Miller T, de Rooij SE, Cunningham C (2008) Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses. J Psychosom Res 65(3):229–238. doi: 10.1016/j.jpsychores.2008.05.019 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Garcia JJ, Lopez-Pingarron L, Almeida-Souza P, Tres A, Escudero P, Garcia-Gil FA, Tan DX, Reiter RJ et al (2014) Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res 56(3):225–237. doi: 10.1111/jpi.12128 CrossRefPubMedGoogle Scholar
  44. 44.
    Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, Reiter RJ (2004) Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 36(1):1–9. doi: 10.1046/j.1600-079X.2003.00092.x CrossRefPubMedGoogle Scholar
  45. 45.
    Alzoubi KH, Mayyas FA, Khabour OF, Bani Salama FM, Alhashimi FH, Mhaidat NM (2015) Chronic Melatonin Treatment Prevents Memory Impairment Induced by Chronic Sleep Deprivation. Mol Neurobiol. doi: 10.1007/s12035-015-9286-z PubMedGoogle Scholar
  46. 46.
    Joshi N, Biswas J, Nath C, Singh S (2014) Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology. Mol Neurobiol. doi: 10.1007/s12035-014-8865-8 Google Scholar
  47. 47.
    Ni Chonchubhair A, Valacio R, Kelly J, O'Keefe S (1995) Use of the abbreviated mental test to detect postoperative delirium in elderly people. Br J Anaesth 75(4):481–482CrossRefPubMedGoogle Scholar
  48. 48.
    Hare M, Wynaden D, McGowan S, Speed G (2008) Assessing cognition in elderly patients presenting to the emergency department. Int Emerg Nurs 16(2):73–79. doi: 10.1016/j.ienj.2008.01.005 CrossRefPubMedGoogle Scholar
  49. 49.
    Jitapunkul S, Pillay I, Ebrahim S (1991) The abbreviated mental test: its use and validity. Age Ageing 20(5):332–336. doi: 10.1093/ageing/20.5.332 CrossRefPubMedGoogle Scholar
  50. 50.
    Vural EM, van Munster BC, de Rooij SE (2014) Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs Aging 31(6):441–451. doi: 10.1007/s40266-014-0178-0 CrossRefPubMedGoogle Scholar
  51. 51.
    Koch BC, Nagtegaal JE, Kerkhof GA, ter Wee PM (2009) Circadian sleep-wake rhythm disturbances in end-stage renal disease. Nat Rev Nephrol 5(7):407–416. doi: 10.1038/nrneph.2009.88 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Sheng Chen
    • 1
  • LiGen Shi
    • 1
  • Feng Liang
    • 1
  • Liang Xu
    • 1
  • Doycheva Desislava
    • 2
  • Qun Wu
    • 1
  • Jianmin Zhang
    • 1
  1. 1.Department of Neurosurgery, Second Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina
  2. 2.Department of Physiology and PharmacologyLoma Linda UniversityLoma LindaUSA

Personalised recommendations